<DOC>
	<DOCNO>NCT01679951</DOCNO>
	<brief_summary>The purpose dose range find study ass effectiveness , safety tolerability JNJ-38518168 dose 3 , 10 , 30 mg/d compare placebo patient active rheumatoid arthritis ( RA ) despite concomitant methotrexate ( MTX ) therapy .</brief_summary>
	<brief_title>A Dose Range Finding Study JNJ-38518168 Patients With Active Rheumatoid Arthritis Spite Treatment With Methotrexate</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician patient know treatment patient receives ) , multicenter , placebo-controlled ( inactive substance compare drug test whether drug real effect clinical trial ) , parallel-group ( group patient treat time ) , dose range find study JNJ-38518168 patient active RA despite concomitant MTX therapy . The study consist screening period , 24-week placebo-controlled period 4-week follow-up period last dose last visit . The duration participation study individual patient 34 week ( include screen ) . The patient assign 1 4 treatment group 1:1:1:1 ratio placebo JNJ-38518168 ( 3 mg 10 mg 30 mg ) . Safety assessment evaluation determine efficacy JNJ-38518168 reduce sign symptom RA perform study visit . Safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Has rheumatoid arthritis least 6 month prior date signing informed consent screen Must positive either anticyclic citrullinated peptide antibody rheumatoid factor serum screening Must active rheumatoid arthritis ( least 6 swollen 6 tender joint use 66/68 joint count time screen baseline Serum C reactive protein great equal 0.80 mg/dL time screening Has treat tolerate methotrexate treatment dosages 10 25 mg/week inclusive , minimum 6 month stable dose least 8 week prior date signing informed consent screening Has inflammatory disease rheumatoid arthritis , include limited adult onset Still 's disease , psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease might confound evaluation benefit study agent therapy Has current sign symptom liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive uncontrolled Has ever receive approved investigational biologic agent rheumatoid indication Has treat nonbiologic disease modify antirheumatic drug within 4 week prior first administration study agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Swollen tender joint</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Immunology</keyword>
	<keyword>Dose range finding study</keyword>
</DOC>